PARPi: Precision Medicine in Advanced Prostate Cancer (2023)

November 14, 2023

COMPLIMENTARY CME VIRTUAL COURSE!

November 14, 2023 | Time: 7:00-8:00 PM ET


The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered. The first in the series, PARPi: Precision Medicine in Advanced Prostate Cancer features a multidisciplinary panel, including a urologist, oncologist, and APP, to present the latest advances in PARPi. The expert faculty will engage in an interactive, case-based discussion amongst each other and engage with the learners through Q&A.

Following this live virtual activity, the course will be captured and posted on AUA’s online learning system, AUAUniversity, and the AUAUniversity YouTube channel for on-demand viewing for up to one year. Additionally, the recording will be released as an individual episode on the very successful AUAUniversity Podcast.

Participants will be asked to complete a Pre-work Library in advance of attending the live virtual courses. The Pre-work Library will include relevant AUA Clinical Guidelines, journal articles and the webcast/podcast of “The Role of PARP Inhibitors in Advanced Prostate Cancer: An AUA/SUO Joint Symposium” presented at the 2023 AUA Annual Meeting.


ACKNOWLEDGEMENT

 

This educational activity is supported by an independent educational grant from:

  • Pfizer, Inc.

 

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider (Nurse Practitioners, Physician Assistants, Nurse Navigators)

Learning Objectives

At the conclusion of this activity, the learner will:

  1.  Describe the mechanism of action of PARP inhibitors and the differences among drugs in this class.
  2.  Describe the role of PARPi treatment alone and in combination with other cancer based therapies.
  3.  Discuss existing clinical trial data assessing the efficacy of PARPi in advanced prostate cancer and ongoing late phase trials for PARP inhibitors.
  4.  Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
10/12/2023
Course expires: 
11/14/2026
Event starts: 
11/14/2023 - 7:00pm EST
Event ends: 
11/14/2023 - 8:00pm EST
Rating: 
0

***Instructions***

  1. Click on the TAKE COURSE button.
  2. Click “Start” under "Live Virtual Course" in the Course Progress pane.
  3. Click on the link provided to register in advance for this course.
  4. After registering, you will receive a confirmation email containing information about joining the course. 

 

EDUCATION COUNCIL DISCLOSURES

PDF icon Education Council Disclosures 2023.pdf

COI REVIEW WORK GROUP DISCLOSURES

PDF icon COI Review Work Group Disclosures_2023.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

 

Course Director(s)

Ashley Ross, MD, PHD

has a financial relationship (Consultant or Advisor (Oncology)) with Myovant;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Blue Earth;.
has a financial relationship (Consultant or Advisor (Oncology)) with Veracyte;.
has a financial relationship (Consultant or Advisor (Oncology)) with TEMPUS;.
has a financial relationship (Consultant or Advisor (Oncology)) with GenomeDx Biosciences;.
has a financial relationship (Consultant or Advisor (Oncology)) with Lantheus;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Janssen;.
Faculty(s)

Emmanuel Antonarakis, MD

has a financial relationship (Scientific Study or Trial (Oncology)) with Novartis;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Orion;.
has a financial relationship (Consultant or Advisor (Oncology)) with Foundation Medicine;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Bayer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer;.
has a financial relationship (Consultant or Advisor (Oncology)) with AstraZeneca;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Hookipa Pharma;.
has a financial relationship (Consultant or Advisor (Oncology)) with Blue Earth Diagnostics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tempus;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Bayer;.
has a financial relationship (Intellectual Property Interest (Oncology)) with QIAGEN;.
has a financial relationship (Consultant or Advisor (Oncology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Propella Therapeutics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Menarini Silicon Biosystems;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Constellation Pharma;.
has a financial relationship (Consultant or Advisor (Oncology)) with Aadi Bioscience;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Bristol Myers-Squibb;.
has a financial relationship (Consultant or Advisor (Oncology)) with Amgen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sanofi;.
has a financial relationship (Consultant or Advisor (Oncology)) with z-Alpha;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with Corcept Therapeutics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Aikido Pharma;.

Caroline Pratz, CRNP,MSN

has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Merck;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Seagen;.

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.

Registration for this Live Virtual Course is complimentary.

To join the live course:

  1. Click on the TAKE COURSE button.
  2. Click “Live Virtual Course” in the Course Progress pane.
  3. Click the link to register in advance.
  4. After registering, you will receive a confirmation email containing information about joining the webinar.

Registration for this course is complimentary; however should you need to cancel your participation for any reason, please let us know at least two weeks before the course by contacting education@auanet.org.


Attendee Information & Policies 

AUA Anti-Harassment Policy 

AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress. 

Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly. 

The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy. 

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA). 

Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. 

Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms. 

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA. 

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.